Your browser doesn't support javascript.
loading
In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy.
Corvigno, Sara; Badal, Sunil; Spradlin, Meredith L; Keating, Michael; Pereira, Igor; Stur, Elaine; Bayraktar, Emine; Foster, Katherine I; Bateman, Nicholas W; Barakat, Waleed; Darcy, Kathleen M; Conrads, Thomas P; Maxwell, G Larry; Lorenzi, Philip L; Lutgendorf, Susan K; Wen, Yunfei; Zhao, Li; Thaker, Premal H; Goodheart, Michael J; Liu, Jinsong; Fleming, Nicole; Lee, Sanghoon; Eberlin, Livia S; Sood, Anil K.
Afiliación
  • Corvigno S; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Badal S; Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
  • Spradlin ML; Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
  • Keating M; Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
  • Pereira I; Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
  • Stur E; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bayraktar E; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Foster KI; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bateman NW; Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Barakat W; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
  • Darcy KM; Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Conrads TP; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
  • Maxwell GL; Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Lorenzi PL; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
  • Lutgendorf SK; Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Wen Y; Women's Health Integrated Research Center, Women's Service Line, Inova Health System, Falls Church, VA, USA.
  • Zhao L; Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Thaker PH; Women's Health Integrated Research Center, Women's Service Line, Inova Health System, Falls Church, VA, USA.
  • Goodheart MJ; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu J; Departments of Psychological and Brain Sciences, Obstetrics and Gynecology, and Urology, University of Iowa, Iowa City, IA, USA.
  • Fleming N; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Eberlin LS; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University, St. Louis, MO, USA.
  • Sood AK; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Iowa, Iowa City, IA, USA.
NPJ Precis Oncol ; 7(1): 115, 2023 Nov 03.
Article en En | MEDLINE | ID: mdl-37923835
ABSTRACT
In this study, we investigated the metabolic alterations associated with clinical response to chemotherapy in patients with ovarian cancer. Pre- and post-neoadjuvant chemotherapy (NACT) tissues from patients with high-grade serous ovarian cancer (HGSC) who had poor response (PR) or excellent response (ER) to NACT were examined. Desorption electrospray ionization mass spectrometry (DESI-MS) was performed on sections of HGSC tissues collected according to a rigorous laparoscopic triage algorithm. Quantitative MS-based proteomics and phosphoproteomics were performed on a subgroup of pre-NACT samples. Highly abundant metabolites in the pre-NACT PR tumors were related to pyrimidine metabolism in the epithelial regions and oxygen-dependent proline hydroxylation of hypoxia-inducible factor alpha in the stromal regions. Metabolites more abundant in the epithelial regions of post-NACT PR tumors were involved in the metabolism of nucleotides, and metabolites more abundant in the stromal regions of post-NACT PR tumors were related to aspartate and asparagine metabolism, phenylalanine and tyrosine metabolism, nucleotide biosynthesis, and the urea cycle. A predictive model built on ions with differential abundances allowed the classification of patients' tumor responses as ER or PR with 75% accuracy (10-fold cross-validation ridge regression model). These findings offer new insights related to differential responses to chemotherapy and could lead to novel actionable targets.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos